Published in Vaccine Weekly, May 17th, 1999
Over the past several years, it has become apparent that new approaches are required to develop an effective vaccine against HIV infection. Boston Biomedica's HIV vaccine program represents a proprietary approach to the generation of a prophylactic or therapeutic vaccine targeting this devastating virus, according to the company.
Wild and his...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly